MenQuadfi® demonstrates superior immune response against serogroup C meningococcal disease in toddlers
Phase 3 study met primary and secondary endpoints demonstrating MenQuadfi® induced superior immune responses to serogroup C compared to a standard-of-care vaccine in healthy toddlers
MenQuadfi is the first and only quadrivalent ACWY vaccine to demonstrate superior immune response against serogroup C in toddlers
July 10, 2021
Results from a head-to-head Phase 3 study, evaluating the immune response of MenQuadfi® to serogroup C, one of the main serogroups of invasive meningococcal disease (IMD), compared to Nimenrix® (quadrivalent ACWY vaccine) and NeisVac-C® (monovalent C vaccine) in healthy toddlers, were presented today in an oral session at the 2021 European Congress of Clinical Microbiology and Infectious Disease.